Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(CSE:
MDMA
)
0.1600
UNCHANGED
Streaming Delayed Price
Updated: 3:00 PM EDT, Apr 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.1600
Bid (Size)
0.1600 (2,000)
Ask (Size)
0.1750 (3,000)
Prev. Close
0.1600
Today's Range
0.1600 - 0.1600
52wk Range
0.0650 - 0.3400
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025
From
PharmAla Biotech
Via
GlobeNewswire
Performance
YTD
-40.7%
-40.7%
1 Month
-11.1%
-11.1%
3 Month
-44.8%
-44.8%
6 Month
+60.0%
+60.0%
1 Year
-25.6%
-25.6%
More News
Read More
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
May 29, 2024
Via
Benzinga
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Begins Trading on OTCQB
September 06, 2023
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023
From
PharmAla Biotech
Via
GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
January 27, 2023
Via
ACCESSWIRE
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
From
Virtual Investor Conferences
Via
GlobeNewswire
PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference
December 13, 2022
From
Virtual Investor Conferences
Via
GlobeNewswire
Frequently Asked Questions
Is MDMA publicly traded?
Yes, MDMA is publicly traded.
What exchange does MDMA trade on?
MDMA trades on the Canadian Securities Exchange
What is the ticker symbol for MDMA?
The ticker symbol for MDMA is MDMA on the Canadian Securities Exchange
What is the current price of MDMA?
The current price of MDMA is 0.1600
When was MDMA last traded?
The last trade of MDMA was at 04/09/25 03:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.